VEGF and ALS: the luckiest growth factor? [Trends Mol Med. 2004] - PubMed

loading

Review VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? [Trends Mol Med. 2004]
Review VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?
Lambrechts D, Storkebaum E, Carmeliet P. Trends Mol Med. 2004 Jun; 10(6):275-82.
A new piece of the ALS puzzle. [Nat Genet. 2003]
A new piece of the ALS puzzle.
Cleveland JL. Nat Genet. 2003 Aug; 34(4):357-8.
Review Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. [Muscle Nerve. 2006]
Review Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.
Bogaert E, Van Damme P, Van Den Bosch L, Robberecht W. Muscle Nerve. 2006 Oct; 34(4):391-405.
Low levels of the vascular endothelial growth factor in CSF from early ALS patients. [Neurology. 2004]
Low levels of the vascular endothelial growth factor in CSF from early ALS patients.
Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V, Destée A, Tonnel AB, Just N. Neurology. 2004 Jun 8; 62(11):2127-9.
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. [Nat Neurosci. 2005]
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, Van Damme P, Rutten B, Man WY, De Mol M, et al. Nat Neurosci. 2005 Jan; 8(1):85-92. Epub 2004 Nov 28.

Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. [J Biol Chem. 2009]
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.
Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK. J Biol Chem. 2009 Oct 16; 284(42):29065-76. Epub 2009 Aug 13.
Review Mechanisms and targets for angiogenic therapy after stroke. [Cell Adh Migr. 2009]
Review Mechanisms and targets for angiogenic therapy after stroke.
Navaratna D, Guo S, Arai K, Lo EH. Cell Adh Migr. 2009 Apr-Jun; 3(2):216-23. Epub 2009 Apr 13.
Review Strategic approaches to developing drug treatments for ALS. [Drug Discov Today. 2008]
Review Strategic approaches to developing drug treatments for ALS.
Vincent AM, Sakowski SA, Schuyler A, Feldman EL. Drug Discov Today. 2008 Jan; 13(1-2):67-72. Epub 2007 Nov 26.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

VEGF and ALS: the luckiest growth factor?
VEGF and ALS: the luckiest growth factor?
Trends Mol Med. 2004 Jan ;10(1):1-3.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed